Amgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk

Reuters2026/07/30 12:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

EMA’s CHMP backed expanding Repatha’s EU use to adults with established atherosclerotic cardiovascular disease or high risk to cut LDL-C.
Opinion was supported by the Phase 3 VESALIUS-CV trial in more than 12,000 high-risk patients without prior heart attack or stroke.
Trial showed a 25% relative risk reduction in a composite of coronary death, myocardial infarction, or ischemic stroke versus placebo.
European Commission decision is expected in the coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607300830PR_NEWS_EUPR__ES_SE14455) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk

You may also like

Crypto prices